HLB surges on FDA approval of new bile duct cancer drug 'Repiktu'

[특징주] HLB, 담관암 신약 '리픽투' FDA 허가에 상한가(종합)

13 reports from 9 outlets in 1 language · first reported 2026-09-27 18:19 UTC · updated 2026-09-28 08:59 UTC · JSON

Reports

1. [특징주] HLB, 담관암 신약 FDA 승인 소식에 …그룹株 줄줄이 ‘상한가’HLB, on the news of FDA approval for a new bile duct cancer drug...Group stocks 'limit up' one after anotherPublished by chosun.com, chosun.com · 2026-09-28 05:40 UTC
2. HLB 그룹주 상한가…담관암 신약 FDA 허가HLB Group's stock price limit... FDA approval for new bile duct cancer drughankyung.com · ko · 2026-09-28 08:59 UTC
3. [특징주] HLB, 담관암 신약 '리픽투' FDA 허가에 상한가(종합)HLB surges on FDA approval of new bile duct cancer drug 'Repiktu'yna.co.kr · ko · 2026-09-28 06:41 UTC
4. 담관암 신약 FDA 허가...HLB그룹주 줄줄이 ‘상한가’ [오늘, 이 종목]Bile duct cancer new drug FDA approved...HLB Group stock soars to 'upper limit' [Today, this stock]mk.co.kr · ko · 2026-09-28 06:00 UTC
5. [ET특징주] HLB, 美 자회사 '담관암 신약' FDA 품목 허가… 그룹주 일제히 상한가[ET feature stock] HLB, US subsidiary 'new bile duct cancer drug' FDA item approval... Group stock rises to upper limitetnews.com · ko · 2026-09-28 02:29 UTC
6. ‘담관암 신약’ FDA 허가 소식에…HLB그룹주 일제히 상한가 직행FDA approval news for 'bile duct cancer drug'...HLB Group shares surge to upper limitmk.co.kr · ko · 2026-09-28 01:21 UTC
7. HLB, 담관암 신약 ‘리픽투’ FDA 허가 소식에 그룹주 줄줄이 상한가 직행HLB, liver cancer new drug 'Ripictu' FDA approval news causes group stocks to surge straight upmk.co.kr · ko · 2026-09-28 00:30 UTC
8. 담관암 치료제 FDA 승인에 HLB그룹주 줄줄이 '상한가'HLB Group shares surge to upper limit after FDA approval of bile duct cancer treatmentnewsis.com · ko · 2026-09-28 00:27 UTC
9. [특징주] "드디어 美 FDA 뚫었다"…HLB그룹주, 담관암 신약 허가에 무더기 '상한가'Finally, the US FDA approved... HLB Group shares surged to the upper limit on the approval of a new drug for bile duct canceretoday.co.kr · ko · 2026-09-28 00:21 UTC
10. [특징주] HLB, 담관암 신약 '리픽투' FDA 허가 소식에 상한가HLB hits upper limit after news of FDA approval for new bile duct cancer drug 'Repictu'yna.co.kr · ko · 2026-09-28 00:17 UTC
11. HLB, 담관암 신약 美 허가 소식에 HLB그룹주 6개 상한가HLB shares hit upper limit after HLB Group receives news of new bile duct cancer drug approval in the USmt.co.kr · ko · 2026-09-28 00:16 UTC
12. HLB, 담관암 신약 美 FDA 허가… 개발전략 다변화 결실HLB, a new drug for bile duct cancer, receives FDA approval in the US... Diversification of development strategy bears fruitmt.co.kr · ko · 2026-09-27 18:19 UTC